Association between mineralocorticoid receptor antagonists and kidney harm: A systematic review and meta‐analysis of randomized controlled trials
- 22 November 2024
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (1) , 43-53
Abstract
Conflicting data have been reported on the association between mineralocorticoid receptor antagonists (MRAs) and acute kidney injury (AKI). This systematic review and meta‐analysis aimed to evaluate whether MRAs affect the risk of AKI. MEDLINE via PubMed, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov website were comprehensively searched to extract all relevant studies. Randomized controlled trials (RCTs) were selected that compared MRA versus placebo or no treatment and had study populations consisting of patients with heart or kidney disease. The primary outcome was AKI. The secondary outcome was kidney injury, including AKI and non‐AKI. Thirty‐three studies were included in the meta‐analysis. MRAs were not associated with an increased risk of AKI (risk ratio [RR] 1.13, 95% confidence interval [CI] 0.88–1.46, p = 0.29, I2 = 15%, 18,065 patients, 13 RCTs, moderate certainty). For the secondary outcome, MRAs were associated with an increased risk of kidney injury (RR 1.52, 95% CI 1.24–1.87, p < 0.01, I2 = 48%, 27,492 patients, 33 RCTs, low certainty). In particular, only canrenone (RR 5.39, 95% CI 2.17–13.37, p < 0.01) and spironolactone (RR 1.78, 95% CI 1.48–2.14, p < 0.01) were associated with an increased risk of kidney injury. However, eplerenone and finerenone seem not to increase the risk of kidney injury in patients with heart or kidney disease. The selection of MRAs might influence the risk of kidney‐associated events. Further studies focusing on individual MRAs may be needed to clarify these differences.Keywords
This publication has 56 references indexed in Scilit:
- Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case–Control Study with a Focus on Medicines Used in Primary CareDrug Safety, 2022
- Mineralocorticoid Receptor Antagonism in Chronic Kidney DiseaseKidney International Reports, 2021
- Epidemiology of Heart FailureEuropean Journal of Heart Failure, 2020
- Effect of Finerenone on Albuminuria in Patients With Diabetic NephropathyJAMA, 2015
- Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trialClinical and Experimental Nephrology, 2015
- Androgen Deprivation Therapy and Risk of Acute Kidney Injury in Patients With Prostate CancerJAMA, 2013
- Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF)Journal of Cardiac Failure, 2011
- Spironolactone Reduced Arrhythmia and Maintained Magnesium Homeostasis in Patients With Congestive Heart FailureJournal of Cardiac Failure, 2007
- Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarctionAmerican Heart Journal, 2005
- Antihypertensive responses to spironolactone in normal renin hypertensionClinical Pharmacology & Therapeutics, 1978